{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477370741
| IUPAC_name               = 3-{[2-(morpholin-4-yl)ethyl]amino}-6-phenylpyridazine-4-carbonitrile
| image                    = Bazinaprine.svg
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number               = 94011-82-2
| ATC_prefix               = None
| ATC_suffix               = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NU8Y4C529J
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 150365
| PubChem                  = 72119
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID             = 65096
| C = 17 | H = 19 | N = 5 | O = 1
| molecular_weight         = 309.366 g/mol
| smiles                   = N#Cc2cc(nnc2NCCN1CCOCC1)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI                 = 1S/C17H19N5O/c18-13-15-12-16(14-4-2-1-3-5-14)20-21-17(15)19-6-7-22-8-10-23-11-9-22/h1-5,12H,6-11H2,(H,19,21)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey              = KRNDIPHOJLIHRI-UHFFFAOYSA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_status             = 
| routes_of_administration = 
}}

'''Bazinaprine''' ('''SR-95,191''') is an experimental drug candidate. It is a [[monoamine oxidase inhibitor]] (MAOI) which is believed to be useful for the treatment of [[depression (mood)|depression]]. The drug strongly inhibits type A [[monoamine oxidase]], but only weakly inhibits type B. The effects of the drug are reversible [[in vivo]], but not [[in vitro]].<ref name=88newderivative>{{cite journal |pmid=3346672 |year=1988 |last1=Kan |first1=JP |last2=Steinberg |first2=R |last3=Leclercq |first3=J |last4=Worms |first4=P |last5=Biziere |first5=K |title=Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: Evidence for selective and reversible inhibition of monoamine oxidase type a in vivo but not in vitro |volume=50 |issue=4 |pages=1137–44 |journal=Journal of Neurochemistry |doi=10.1111/j.1471-4159.1988.tb10584.x}}</ref>  In studies, the chemical has been shown to not interact ''in vivo'' with other neurotransmitter or drug receptor sites.<ref name=87MAOI>{{cite journal |pmid=3100771 |year=1987 |last1=Kan |first1=JP |last2=Steinberg |first2=R |last3=Mouget-Goniot |first3=C |last4=Worms |first4=P |last5=Bizière |first5=K |title=SR 95191, a selective inhibitor of type a monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition |volume=240 |issue=1 |pages=251–8 |journal=The Journal of Pharmacology and Experimental Therapeutics |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3100771}}</ref> 

== See also ==
* [[Reversible inhibitor of monoamine oxidase A|Reversible inhibitor of MAO-A]] (RIMA)

== References ==
{{Reflist}}


{{Antidepressants}}
{{Monoamine metabolism modulators}}

[[Category:Monoamine oxidase inhibitors]]
[[Category:Morpholines]]
[[Category:Nitriles]]
[[Category:Pyridazines]]